Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel

Apriliana Cahya Khayrani, Hafizah Mahmud, Aung Ko Ko Oo, Maram H. Zahra, Miharu Oze, Juan Du, Md Jahangir Alam, Said M. Afify, Hagar A.Abu Quora, Tsukasa Shigehiro, Anna Sanchez Calle, Nobuhiro Okada, Akimasa Seno, Koki Fujita, Hiroki Hamada, Yuhki Seno, Tadakatsu Mandai, Masaharu Seno

Research output: Contribution to journalArticle

Abstract

Paclitaxel (PTX) is one of the front-line drugs approved for the treatment of ovarian cancer. However, the application of PTX is limited due to the significant hydrophobicity and poor pharmacokinetics. We previously reported target-directed liposomes carrying tumor-selective conjugated antibody and encapsulated glycosylated PTX (gPTX-L) which successfully overcome the PTX limitation. The tubulin stabilizing activity of gPTX was equivalent to that of PTX while the cytotoxic activity of gPTX was reduced. In human ovarian cancer cell lines, SK-OV-3 and OVK18, the concentration at which cell growth was inhibited by 50% (IC50) for gPTX range from 15⁻20 nM, which was sensitive enough to address gPTX-L with tumor-selective antibody coupling for ovarian cancer therapy. The cell membrane receptor CD44 is associated with cancer progression and has been recognized as a cancer stem cell marker including ovarian cancer, becoming a suitable candidate to be targeted by gPTX-L therapy. In this study, gPTX-loading liposomes conjugated with anti-CD44 antibody (gPTX-IL) were assessed for the efficacy of targeting CD44-positive ovarian cancer cells. We successfully encapsulated gPTX into liposomes with the loading efficiency (LE) more than 80% in both of gPTX-L and gPTX-IL with a diameter of approximately 100 nm with efficacy of enhanced cytotoxicity in vitro and of convenient treatment in vivo. As the result, gPTX-IL efficiently suppressed tumor growth in vivo. Therefore gPTX-IL could be a promising formulation for effective ovarian cancer therapies.

Original languageEnglish
JournalInternational journal of molecular sciences
Volume20
Issue number5
DOIs
Publication statusPublished - Feb 27 2019

Fingerprint

encapsulating
Liposomes
Paclitaxel
Antibodies
Ovarian Neoplasms
Tumors
cancer
Cells
Pharmacokinetics
antibodies
Cell growth
Cell membranes
Cytotoxicity
Hydrophobicity
Stem cells
therapy
tumors
Neoplasm Antibodies
Therapeutics
Neoplasms

Keywords

  • CD44
  • glycosylated paclitaxel
  • liposome
  • modified paclitaxel
  • ovarian cancer
  • specific targeting

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel. / Khayrani, Apriliana Cahya; Mahmud, Hafizah; Oo, Aung Ko Ko; Zahra, Maram H.; Oze, Miharu; Du, Juan; Alam, Md Jahangir; Afify, Said M.; Quora, Hagar A.Abu; Shigehiro, Tsukasa; Calle, Anna Sanchez; Okada, Nobuhiro; Seno, Akimasa; Fujita, Koki; Hamada, Hiroki; Seno, Yuhki; Mandai, Tadakatsu; Seno, Masaharu.

In: International journal of molecular sciences, Vol. 20, No. 5, 27.02.2019.

Research output: Contribution to journalArticle

Khayrani, AC, Mahmud, H, Oo, AKK, Zahra, MH, Oze, M, Du, J, Alam, MJ, Afify, SM, Quora, HAA, Shigehiro, T, Calle, AS, Okada, N, Seno, A, Fujita, K, Hamada, H, Seno, Y, Mandai, T & Seno, M 2019, 'Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel', International journal of molecular sciences, vol. 20, no. 5. https://doi.org/10.3390/ijms20051042
Khayrani, Apriliana Cahya ; Mahmud, Hafizah ; Oo, Aung Ko Ko ; Zahra, Maram H. ; Oze, Miharu ; Du, Juan ; Alam, Md Jahangir ; Afify, Said M. ; Quora, Hagar A.Abu ; Shigehiro, Tsukasa ; Calle, Anna Sanchez ; Okada, Nobuhiro ; Seno, Akimasa ; Fujita, Koki ; Hamada, Hiroki ; Seno, Yuhki ; Mandai, Tadakatsu ; Seno, Masaharu. / Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel. In: International journal of molecular sciences. 2019 ; Vol. 20, No. 5.
@article{2f9171add8ac4b5db344d02a931fe032,
title = "Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel",
abstract = "Paclitaxel (PTX) is one of the front-line drugs approved for the treatment of ovarian cancer. However, the application of PTX is limited due to the significant hydrophobicity and poor pharmacokinetics. We previously reported target-directed liposomes carrying tumor-selective conjugated antibody and encapsulated glycosylated PTX (gPTX-L) which successfully overcome the PTX limitation. The tubulin stabilizing activity of gPTX was equivalent to that of PTX while the cytotoxic activity of gPTX was reduced. In human ovarian cancer cell lines, SK-OV-3 and OVK18, the concentration at which cell growth was inhibited by 50{\%} (IC50) for gPTX range from 15⁻20 nM, which was sensitive enough to address gPTX-L with tumor-selective antibody coupling for ovarian cancer therapy. The cell membrane receptor CD44 is associated with cancer progression and has been recognized as a cancer stem cell marker including ovarian cancer, becoming a suitable candidate to be targeted by gPTX-L therapy. In this study, gPTX-loading liposomes conjugated with anti-CD44 antibody (gPTX-IL) were assessed for the efficacy of targeting CD44-positive ovarian cancer cells. We successfully encapsulated gPTX into liposomes with the loading efficiency (LE) more than 80{\%} in both of gPTX-L and gPTX-IL with a diameter of approximately 100 nm with efficacy of enhanced cytotoxicity in vitro and of convenient treatment in vivo. As the result, gPTX-IL efficiently suppressed tumor growth in vivo. Therefore gPTX-IL could be a promising formulation for effective ovarian cancer therapies.",
keywords = "CD44, glycosylated paclitaxel, liposome, modified paclitaxel, ovarian cancer, specific targeting",
author = "Khayrani, {Apriliana Cahya} and Hafizah Mahmud and Oo, {Aung Ko Ko} and Zahra, {Maram H.} and Miharu Oze and Juan Du and Alam, {Md Jahangir} and Afify, {Said M.} and Quora, {Hagar A.Abu} and Tsukasa Shigehiro and Calle, {Anna Sanchez} and Nobuhiro Okada and Akimasa Seno and Koki Fujita and Hiroki Hamada and Yuhki Seno and Tadakatsu Mandai and Masaharu Seno",
year = "2019",
month = "2",
day = "27",
doi = "10.3390/ijms20051042",
language = "English",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel

AU - Khayrani, Apriliana Cahya

AU - Mahmud, Hafizah

AU - Oo, Aung Ko Ko

AU - Zahra, Maram H.

AU - Oze, Miharu

AU - Du, Juan

AU - Alam, Md Jahangir

AU - Afify, Said M.

AU - Quora, Hagar A.Abu

AU - Shigehiro, Tsukasa

AU - Calle, Anna Sanchez

AU - Okada, Nobuhiro

AU - Seno, Akimasa

AU - Fujita, Koki

AU - Hamada, Hiroki

AU - Seno, Yuhki

AU - Mandai, Tadakatsu

AU - Seno, Masaharu

PY - 2019/2/27

Y1 - 2019/2/27

N2 - Paclitaxel (PTX) is one of the front-line drugs approved for the treatment of ovarian cancer. However, the application of PTX is limited due to the significant hydrophobicity and poor pharmacokinetics. We previously reported target-directed liposomes carrying tumor-selective conjugated antibody and encapsulated glycosylated PTX (gPTX-L) which successfully overcome the PTX limitation. The tubulin stabilizing activity of gPTX was equivalent to that of PTX while the cytotoxic activity of gPTX was reduced. In human ovarian cancer cell lines, SK-OV-3 and OVK18, the concentration at which cell growth was inhibited by 50% (IC50) for gPTX range from 15⁻20 nM, which was sensitive enough to address gPTX-L with tumor-selective antibody coupling for ovarian cancer therapy. The cell membrane receptor CD44 is associated with cancer progression and has been recognized as a cancer stem cell marker including ovarian cancer, becoming a suitable candidate to be targeted by gPTX-L therapy. In this study, gPTX-loading liposomes conjugated with anti-CD44 antibody (gPTX-IL) were assessed for the efficacy of targeting CD44-positive ovarian cancer cells. We successfully encapsulated gPTX into liposomes with the loading efficiency (LE) more than 80% in both of gPTX-L and gPTX-IL with a diameter of approximately 100 nm with efficacy of enhanced cytotoxicity in vitro and of convenient treatment in vivo. As the result, gPTX-IL efficiently suppressed tumor growth in vivo. Therefore gPTX-IL could be a promising formulation for effective ovarian cancer therapies.

AB - Paclitaxel (PTX) is one of the front-line drugs approved for the treatment of ovarian cancer. However, the application of PTX is limited due to the significant hydrophobicity and poor pharmacokinetics. We previously reported target-directed liposomes carrying tumor-selective conjugated antibody and encapsulated glycosylated PTX (gPTX-L) which successfully overcome the PTX limitation. The tubulin stabilizing activity of gPTX was equivalent to that of PTX while the cytotoxic activity of gPTX was reduced. In human ovarian cancer cell lines, SK-OV-3 and OVK18, the concentration at which cell growth was inhibited by 50% (IC50) for gPTX range from 15⁻20 nM, which was sensitive enough to address gPTX-L with tumor-selective antibody coupling for ovarian cancer therapy. The cell membrane receptor CD44 is associated with cancer progression and has been recognized as a cancer stem cell marker including ovarian cancer, becoming a suitable candidate to be targeted by gPTX-L therapy. In this study, gPTX-loading liposomes conjugated with anti-CD44 antibody (gPTX-IL) were assessed for the efficacy of targeting CD44-positive ovarian cancer cells. We successfully encapsulated gPTX into liposomes with the loading efficiency (LE) more than 80% in both of gPTX-L and gPTX-IL with a diameter of approximately 100 nm with efficacy of enhanced cytotoxicity in vitro and of convenient treatment in vivo. As the result, gPTX-IL efficiently suppressed tumor growth in vivo. Therefore gPTX-IL could be a promising formulation for effective ovarian cancer therapies.

KW - CD44

KW - glycosylated paclitaxel

KW - liposome

KW - modified paclitaxel

KW - ovarian cancer

KW - specific targeting

UR - http://www.scopus.com/inward/record.url?scp=85062403535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062403535&partnerID=8YFLogxK

U2 - 10.3390/ijms20051042

DO - 10.3390/ijms20051042

M3 - Article

C2 - 30818864

AN - SCOPUS:85062403535

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 5

ER -